Registry of Acute Coronary Syndrome From University Hospital of Vigo

Registry of Patients Admitted by Acute Coronary Syndrome to University Hospital of Vigo

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03664388

Acronym

CardioCHUVI

Enrollment

8000

Registered

2018-09-10

Start date

2016-02-01

Completion date

2020-02-01

Last updated

2018-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

Acute Coronary Syndrome; Bleeding; Dual antiplatelet therapy

Brief summary

CardoCHUVI registry was aim to study ischemic and bleeding complication after an acute coronary syndrome (ACS), both in-hospital and follow-up events.

Detailed description

CardioCHUVI is a retrospective study aim to analyze all consecutively patients admitted by acute coronary syndrome to University Hospital Alvaro Cunqueiro of Vigo, between January 2010 to January 2018 The objective of the project was to study cardiac and bleeding complications, such as reinfarction, heart failure, atrial fibrillation, stroke, and bleeding events, together with all-cause and cardiac mortality

Interventions

DRUGDual antiplatelet therapy with ticagrelor/prasuglre

Compare bleeding and ischemic events according to the type and duration of dual antiplatelet therapy

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Any patient admitted to University Hospital Alvaro Cunqueiro of Vigo for acute coronary syndrome.

Exclusion criteria

* Secondary acute coronary syndromes during a hospital admission for another cause (i.e. acute myocardial infarction in the context of a sepsis)

Design outcomes

Primary

Measure	Time frame	Description
All cause mortality	Through study completion, an average of 3 years	Death for any cause

Secondary

Measure	Time frame	Description
Bleeding	Through study completion, an average of 3 years	Any bleeding according to BARC definition (from 1 to 5)
Ischemic stroke	Through study completion, an average of 3 years	Ischemic stroke documented in CT
Reinfarction	Through study completion, an average of 3 years	New spontaneous acute myocardial infarction
Heart Failure	Through study completion, an average of 3 years	Heart Failure admissions
Atrial Fibrillation	Through study completion, an average of 3 years	Atrial fibrillation documented in ECG
Cancer	Through study completion, an average of 3 years	Any type of malignant cancer

Countries

Spain

Contacts

Primary ContactSergio Raposeiras Roubín, MD, PhD

raposeiras26@hotmail.com0034 620170387

Backup ContactEmad Abu Assi, MD, PhD

eabuassi@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026